GAITHERSBURG, Md. and SUZHOU BIOBAY, China, July 1, 2021 /PRNewswire/ — Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed $105 million in a Series E financing. This round of funding was led by Rotating Boulder Fund, an investor that has been supporting the company since its Series B round, with participation from existing investors and a well-recognized syndicate of new investors.
{iframe}https://biobuzz.io/gaithersburgs-sirnaomics-secures-105-million-in-series-e-financing-to-fund-development-of-novel-rnai-therapeutics/{/iframe}